| AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Transl Res 2011;3(5):404-421
Review Article
Strategies to harness immunity against infectious pathogens after
haploidentical stem cell transplantation
Sergio Rutella, Franco Locatelli
Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children Hospital, Rome, Italy; Catholic
University Medical School, Rome, Italy; University of Pavia, Italy.
Received July 18, 2011; accepted August 26, 2011; Epub September 10, 2011; Published October 31, 2011
Abstract: Viral and fungal infections account for significant morbidity and mortality, particularly in pediatric
patients with profound immune suppression resulting from allogeneic hematopoietic stem cell transplantation
(HSCT). Therapies with anti-viral and anti-fungal drugs are often associated with significant toxicity, are of limited
efficacy and can induce drug resistance. One innovative approach to prevent and/or treat viral and fungal
infections involves the adoptive transfer of in vitro-expanded or in vitro-generated pathogen-specific T cells. This
review summarizes the clinical trials that have been run to date with virus- and fungus-specific T cells, with
special emphasis on the clinical context of haploidentical HSCT for pediatric malignancies. It will also discuss
initiatives and strategies to overcome the hurdles associated with time-consuming and complex GMP-grade
laboratory procedures required to generate pathogen-specific T cells. (AJTR1107003).
Keywords: Cytomegalovirus, adenovirus, Epstein-Barr virus, Aspergillus, Candida, immune reconstitution, stem
cell transplantation, adoptive cell therapy
Full Text PDF
Address all correspondence to:
Sergio Rutella, MD, PhD
Department of Pediatric Hematology/Oncology
Immunotherapy Program
Bambino Gesù Children Hospital
Piazza S. Onofrio, 4
00165 Rome, Italy
Phone: +39-06-68592678
Fax: +39-06-68592292
E-mail: srutella@rm.unicatt.it
Review Article
Strategies to harness immunity against infectious pathogens after
haploidentical stem cell transplantation
Sergio Rutella, Franco Locatelli
Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children Hospital, Rome, Italy; Catholic
University Medical School, Rome, Italy; University of Pavia, Italy.
Received July 18, 2011; accepted August 26, 2011; Epub September 10, 2011; Published October 31, 2011
Abstract: Viral and fungal infections account for significant morbidity and mortality, particularly in pediatric
patients with profound immune suppression resulting from allogeneic hematopoietic stem cell transplantation
(HSCT). Therapies with anti-viral and anti-fungal drugs are often associated with significant toxicity, are of limited
efficacy and can induce drug resistance. One innovative approach to prevent and/or treat viral and fungal
infections involves the adoptive transfer of in vitro-expanded or in vitro-generated pathogen-specific T cells. This
review summarizes the clinical trials that have been run to date with virus- and fungus-specific T cells, with
special emphasis on the clinical context of haploidentical HSCT for pediatric malignancies. It will also discuss
initiatives and strategies to overcome the hurdles associated with time-consuming and complex GMP-grade
laboratory procedures required to generate pathogen-specific T cells. (AJTR1107003).
Keywords: Cytomegalovirus, adenovirus, Epstein-Barr virus, Aspergillus, Candida, immune reconstitution, stem
cell transplantation, adoptive cell therapy
Full Text PDF
Address all correspondence to:
Sergio Rutella, MD, PhD
Department of Pediatric Hematology/Oncology
Immunotherapy Program
Bambino Gesù Children Hospital
Piazza S. Onofrio, 4
00165 Rome, Italy
Phone: +39-06-68592678
Fax: +39-06-68592292
E-mail: srutella@rm.unicatt.it
 | |  | |  | |  | |  | |  | |  |